PANEL: Achieve New Heights in HPV Vaccination Rates: Start at Age 9 - Dr. Rebecca Perkins

Data continue to show the HPV vaccine is safe and effective, yet HPV vaccination rates remain well below national goals and other vaccines that are part of the “adolescent platform.” What can the evidence tell us about the potential benefits and challenges of routinely starting HPV vaccination at age nine? Would starting HPV vaccination at age nine increase HPV uptake and on-time completion? Are providers willing to recommend HPV vaccine at age nine and is it an easier interaction with parents when they do? What does this practice look like in an actual clinic? This panel will explore answers to these questions and more.

About Dr. Rebecca Perkins

Dr. Perkins is an Associate Professor of Obstetrics and Gynecology at Boston University School of Medicine and Boston Medical Center. Her career is dedicated to reducing health disparities in cervical cancer. Her current research focuses on improving utilization of HPV vaccination and cervical cancer screening guidelines. She was Co-Chair and one of the lead authors of the 2019 ASCCP Risk-Based Management Consensus Guidelines, and Co-Chaired the President’s Cancer Panel Cervical Cancer Subcommittee. She currently serves as co-Chair of the National HPV Vaccination Roundtable.
------------------

The Human Papillomavirus (HPV) vaccination can help prevent 6 types of cancer. Find accurate, evidence-based information about the HPV vaccine, virus, cancer prevention, and science from National HPV Vaccination Roundtable. Hosted by the American Cancer Society, the National HPV Vaccination Roundtable includes experts from 70+ immunization organizations representing nonprofits, universities, researchers, cancer survivors, and healthcare providers.

For more from the National HPV Roundtable: